Navigation Links
Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
Date:4/24/2012

NANJING, China, April 24, 2012 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2012 on Wednesday, May 9, 2012, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Wednesday, May 9, at 8 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:International toll:+65.6723.9381United States toll-free:+1.866.519.4004United States toll:+1.718.354.1231China Domestic toll:800.819.0121 China Domestic mobile toll:400.620.8038 Hong Kong toll:+852.2475.0994Please ask to be connected to Q1 2012 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 73500159.Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:+1.866.214.5335United States toll:+1.718.354.1232The passcode for replay participants is 73500159. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.Investor and Media Contacts: Email: ir@simcere.com In Nanjing:In the United States:Yehong ZhangCindy ZhengPresidentBrunswick GroupSimcere Pharmaceutical GroupTel: 1-212-333-3810Tel: 86-25-8556-6666 ext. 8811In Beijing:In Hong Kong:Yue YuJoseph Lo Chi-LunBrunswick GroupBrunswick GroupTel: 86-10-5960-8Tel: 852-3512-5000   

 

 


'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Full Year 2011 Results
2. Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound
3. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2011 Results
4. Simcere Pharmaceutical Group to Announce Third Quarter 2011 Financial Results on Monday, November 14, 2011
5. Simceres Iremod Receives SFDA New Drug Approval
6. Simceres Branded Generic Formulation Biqi Passes EU-GMP Inspection
7. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2011 Results
8. Simcere Pharmaceutical Group to Announce Second Quarter 2011 Financial Results on Tuesday, August 9, 2011
9. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
10. Simcere Pharmaceutical Group Filed 2010 Annual Report on Form 20-F
11. Simcere Announces Recent Progress of Qiangkes Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... GAITHERSBURG, Md. , June 7, 2017  Novavax, Inc., ... the second of two Phase 2 trials of its RSV ... women of child bearing age have been published in the ... this publication have been shared in prior scientific conferences). The ... trial in April 2014. Novavax is developing the RSV F ...
(Date:6/2/2017)...  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company ... demonstrating positive biochemical outcomes related to more frequent hemodialysis ... will be presented at the ERA-EDTA Congress being held ... . The research was conducted by ... Europe (KIHDNEy) Cohort team ...
(Date:5/29/2017)... Israel, May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... technology which enables the functional selection of stem cells, ... for the first quarter ended March 31 st , ... our accomplishments in the first quarter of 2017," said ... quarter, we announced the treatment of the first blood ...
Breaking Medicine Technology:
(Date:6/26/2017)... TX (PRWEB) , ... June 26, 2017 , ... ... their coding staff, and consumers are seeing lots of red these days. According ... contain inaccurate charges that result from medical coding errors(1). Some studies point to ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... New patients ... from Dr. Angela Cotey, with or without a referral. Dr. Cotey is a trusted ... of this preferred tooth replacement option. , Patients with missing teeth in Fitchburg, WI, ...
(Date:6/25/2017)... Aliso Viejo, CA (PRWEB) , ... June 24, 2017 , ... Create a feel-good lyric ... place presets above footage and sound in the timeline and write in the lyrics to ... screen before flying back out. Each line of the text can be added modularly for ...
(Date:6/25/2017)... ... , ... An increase in wetter weather in the Northern California area naturally ... a humdinger of an allergy season. A relief from drought conditions is most welcome, ... and weed pollen. , “Our patients have been reporting the typical allergy season ...
(Date:6/25/2017)... ... June 25, 2017 , ... With a heatwave currently bearing down on Northern California ... at the pool. Being swimsuit ready is easy with laser hair removal. , The ... can be a burdensome routine when all you want to do is get out, dive ...
Breaking Medicine News(10 mins):